Cargando…

Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System

Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease of the central nervous system (CNS) that yields to neuronal axon damage, demyelization, and paralysis. Although several drugs were designed for the treatment of MS, with some of them being approved in the last few decades, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chountoulesi, Maria, Demetzos, Costas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349417/
https://www.ncbi.nlm.nih.gov/pubmed/32498357
http://dx.doi.org/10.3390/brainsci10060338
_version_ 1783557059284828160
author Chountoulesi, Maria
Demetzos, Costas
author_facet Chountoulesi, Maria
Demetzos, Costas
author_sort Chountoulesi, Maria
collection PubMed
description Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease of the central nervous system (CNS) that yields to neuronal axon damage, demyelization, and paralysis. Although several drugs were designed for the treatment of MS, with some of them being approved in the last few decades, the complete remission and the treatment of progressive forms still remain a matter of debate and a medical challenge. Nanotechnology provides a variety of promising therapeutic tools that can be applied for the treatment of MS, overcoming the barriers and the limitations of the already existing immunosuppressive and biological therapies. In the present review, we explore literature case studies on the development of drug delivery nanosystems for the targeted delivery of MS drugs in the pathological tissues of the CNS, providing high bioavailability and enhanced therapeutic efficiency, as well as nanosystems for the delivery of agents to facilitate efficient remyelination. Moreover, we present examples of tolerance-inducing nanocarriers, being used as promising vaccines for antigen-specific immunotherapy of MS. We emphasize on liposomes, as well as lipid- and polymer-based nanoparticles. Finally, we highlight the future perspectives given by the nanotechnology field toward the improvement of the current treatment of MS and its animal model, experimental autoimmune encephalomyelitis (EAE).
format Online
Article
Text
id pubmed-7349417
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73494172020-07-14 Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System Chountoulesi, Maria Demetzos, Costas Brain Sci Review Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease of the central nervous system (CNS) that yields to neuronal axon damage, demyelization, and paralysis. Although several drugs were designed for the treatment of MS, with some of them being approved in the last few decades, the complete remission and the treatment of progressive forms still remain a matter of debate and a medical challenge. Nanotechnology provides a variety of promising therapeutic tools that can be applied for the treatment of MS, overcoming the barriers and the limitations of the already existing immunosuppressive and biological therapies. In the present review, we explore literature case studies on the development of drug delivery nanosystems for the targeted delivery of MS drugs in the pathological tissues of the CNS, providing high bioavailability and enhanced therapeutic efficiency, as well as nanosystems for the delivery of agents to facilitate efficient remyelination. Moreover, we present examples of tolerance-inducing nanocarriers, being used as promising vaccines for antigen-specific immunotherapy of MS. We emphasize on liposomes, as well as lipid- and polymer-based nanoparticles. Finally, we highlight the future perspectives given by the nanotechnology field toward the improvement of the current treatment of MS and its animal model, experimental autoimmune encephalomyelitis (EAE). MDPI 2020-06-02 /pmc/articles/PMC7349417/ /pubmed/32498357 http://dx.doi.org/10.3390/brainsci10060338 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chountoulesi, Maria
Demetzos, Costas
Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
title Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
title_full Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
title_fullStr Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
title_full_unstemmed Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
title_short Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
title_sort promising nanotechnology approaches in treatment of autoimmune diseases of central nervous system
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349417/
https://www.ncbi.nlm.nih.gov/pubmed/32498357
http://dx.doi.org/10.3390/brainsci10060338
work_keys_str_mv AT chountoulesimaria promisingnanotechnologyapproachesintreatmentofautoimmunediseasesofcentralnervoussystem
AT demetzoscostas promisingnanotechnologyapproachesintreatmentofautoimmunediseasesofcentralnervoussystem